schliessen

Filtern

 

Bibliotheken

Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer

CONTEXT:: Studies suggested a potential value of preablative stimulated thyroglobulin (ps-Tg) on predicting the recurrent and persistent diseases of differentiated thyroid cancer, whereas its correlations with therapeutic response remain uncertain. OBJECTIVE:: To establish the correlation between ps... Full description

Journal Title: The Journal of Clinical Endocrinology & Metabolism 2016, Vol.101(3), pp.1307-1313
Main Author: Yang, Xue
Other Authors: Liang, Jun , Li, Tianjun , Zhao, Teng , Lin, Yansong
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 0021-972X ; DOI: 10.1210/jc.2015-4016
Link: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201603000-00066
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: ovid00004678-201603000-00066
title: Preablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer
format: Article
creator:
  • Yang, Xue
  • Liang, Jun
  • Li, Tianjun
  • Zhao, Teng
  • Lin, Yansong
subjects:
  • Medicine
ispartof: The Journal of Clinical Endocrinology & Metabolism, 2016, Vol.101(3), pp.1307-1313
description: CONTEXT:: Studies suggested a potential value of preablative stimulated thyroglobulin (ps-Tg) on predicting the recurrent and persistent diseases of differentiated thyroid cancer, whereas its correlations with therapeutic response remain uncertain. OBJECTIVE:: To establish the correlation between ps-Tg and therapeutic response proposed in 2015 American Thyroid Association guidelines, and calculate a cutoff ps-Tg threshold for predicting a poor response. DESIGN/SETTING:: Patients who underwent total thyroidectomy and radioactive iodine therapy in a university hospital participated in this retrospective study. PATIENTS:: Totally, 452 patients with differentiated thyroid cancer were followed for a median of 38 months and were divided into three groups in terms of ps-Tg level: group 1, less than 1 ng/ml (n = 82); group 2, 1–10 ng/ml (n = 173); and group 3, at least 10 ng/ml (n = 197). MAIN OUTCOME MEASURE:: Clinical outcomes were assessed based on response to therapy restaging system, dividing responses into excellent, indeterminate, biomedical incomplete, and structural incomplete (SIR). RESULTS:: Therapeutic responses could be obviously distinguished by different ps-Tg strata. SIR was identified in none of group 1, 1.73% of group 2, and 42.74% of group 3, respectively (χ = 123.037, P < .001). A cutoff value of ps-Tg at 26.75 ng/ml was obtained by receiver operating characteristic curve for differentiating SIR from either excellent, indeterminate, or biomedical incomplete responses. The area under curve was 0.947 and negative predictive value was 96.99%. Ps-Tg was an independent predictive variable of SIR (odds ratio, 42.312; P < .001). CONCLUSIONS:: Ps-Tg has a great performance in predicting therapeutic response and providing incremental value for decision making of radioactive iodine therapy, especially for patients with high ps-Tg level.
language:
source:
identifier: ISSN: 0021-972X ; DOI: 10.1210/jc.2015-4016
fulltext: fulltext
issn:
  • 0021-972X
  • 0021972X
url: Link


@attributes
ID926811450
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid00004678-201603000-00066
sourceidovid
recordidTN_ovid00004678-201603000-00066
sourceformatXML
sourcesystemPC
pqid1770878842
display
typearticle
titlePreablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer
creatorYang, Xue ; Liang, Jun ; Li, Tianjun ; Zhao, Teng ; Lin, Yansong
ispartofThe Journal of Clinical Endocrinology & Metabolism, 2016, Vol.101(3), pp.1307-1313
identifierISSN: 0021-972X ; DOI: 10.1210/jc.2015-4016
descriptionCONTEXT:: Studies suggested a potential value of preablative stimulated thyroglobulin (ps-Tg) on predicting the recurrent and persistent diseases of differentiated thyroid cancer, whereas its correlations with therapeutic response remain uncertain. OBJECTIVE:: To establish the correlation between ps-Tg and therapeutic response proposed in 2015 American Thyroid Association guidelines, and calculate a cutoff ps-Tg threshold for predicting a poor response. DESIGN/SETTING:: Patients who underwent total thyroidectomy and radioactive iodine therapy in a university hospital participated in this retrospective study. PATIENTS:: Totally, 452 patients with differentiated thyroid cancer were followed for a median of 38 months and were divided into three groups in terms of ps-Tg level: group 1, less than 1 ng/ml (n = 82); group 2, 1–10 ng/ml (n = 173); and group 3, at least 10 ng/ml (n = 197). MAIN OUTCOME MEASURE:: Clinical outcomes were assessed based on response to therapy restaging system, dividing responses into excellent, indeterminate, biomedical incomplete, and structural incomplete (SIR). RESULTS:: Therapeutic responses could be obviously distinguished by different ps-Tg strata. SIR was identified in none of group 1, 1.73% of group 2, and 42.74% of group 3, respectively (χ = 123.037, P < .001). A cutoff value of ps-Tg at 26.75 ng/ml was obtained by receiver operating characteristic curve for differentiating SIR from either excellent, indeterminate, or biomedical incomplete responses. The area under curve was 0.947 and negative predictive value was 96.99%. Ps-Tg was an independent predictive variable of SIR (odds ratio, 42.312; P < .001). CONCLUSIONS:: Ps-Tg has a great performance in predicting therapeutic response and providing incremental value for decision making of radioactive iodine therapy, especially for patients with high ps-Tg level.
source
subjectMedicine;
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201603000-00066$$EView_record_at_Wolters_Kluwer_Health_Ovid_Technologies
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutOvid.html$$EView_Wolters_Kluwer_Health,_Lippincott,_Williams_&_Wilkins_Copyright_Statement
search
creatorcontrib
0Yang, Xue
1Liang, Jun
2Li, Tianjun
3Zhao, Teng
4Lin, Yansong
titlePreablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer
descriptionCONTEXT:: Studies suggested a potential value of preablative stimulated thyroglobulin (ps-Tg) on predicting the recurrent and persistent diseases of differentiated thyroid cancer, whereas its correlations with therapeutic response remain uncertain. OBJECTIVE:: To establish the correlation between ps-Tg and therapeutic response proposed in 2015 American Thyroid Association guidelines, and calculate a cutoff ps-Tg threshold for predicting a poor response. DESIGN/SETTING:: Patients who underwent total thyroidectomy and radioactive iodine therapy in a university hospital participated in this retrospective study. PATIENTS:: Totally, 452 patients with differentiated thyroid cancer were followed for a median of 38 months and were divided into three groups in terms of ps-Tg level: group 1, less than 1 ng/ml (n = 82); group 2, 1–10 ng/ml (n = 173); and group 3, at least 10 ng/ml (n = 197). MAIN OUTCOME MEASURE:: Clinical outcomes were assessed based on response to therapy restaging system, dividing responses into excellent, indeterminate, biomedical incomplete, and structural incomplete (SIR). RESULTS:: Therapeutic responses could be obviously distinguished by different ps-Tg strata. SIR was identified in none of group 1, 1.73% of group 2, and 42.74% of group 3, respectively (χ = 123.037, P < .001). A cutoff value of ps-Tg at 26.75 ng/ml was obtained by receiver operating characteristic curve for differentiating SIR from either excellent, indeterminate, or biomedical incomplete responses. The area under curve was 0.947 and negative predictive value was 96.99%. Ps-Tg was an independent predictive variable of SIR (odds ratio, 42.312; P < .001). CONCLUSIONS:: Ps-Tg has a great performance in predicting therapeutic response and providing incremental value for decision making of radioactive iodine therapy, especially for patients with high ps-Tg level.
general
010.1210/jc.2015-4016
1Copyright © 2016 by The Endocrine Society
2Lippincott Williams & Wilkins - Journals
sourceidovid
recordidovid00004678-201603000-00066
issn
00021-972X
10021972X
rsrctypearticle
creationdate2016
addtitleThe Journal of Clinical Endocrinology & Metabolism
searchscopeovid
scopeovid
lsr30VSR-Enriched:[subject, pqid, eissn]
sort
titlePreablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer
authorYang, Xue ; Liang, Jun ; Li, Tianjun ; Zhao, Teng ; Lin, Yansong
creationdate20160300
facets
frbrgroupid4857298555220668271
frbrtype5
creationdate2016
collectionLippincott Williams & Wilkins Journals (Wolters Kluwer Health)
prefilterarticles
rsrctypearticles
creatorcontrib
0Yang, Xue
1Liang, Jun
2Li, Tianjun
3Zhao, Teng
4Lin, Yansong
jtitleJournal of Clinical Endocrinology & Metabolism
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Yang
1Liang
2Li
3Zhao
4Lin
aufirst
0Xue
1Jun
2Tianjun
3Teng
4Yansong
au
0Yang, Xue
1Liang, Jun
2Li, Tianjun
3Zhao, Teng
4Lin, Yansong
atitlePreablative Stimulated Thyroglobulin Correlates to New Therapy Response System in Differentiated Thyroid Cancer
jtitleThe Journal of Clinical Endocrinology & Metabolism
risdate201603
volume101
issue3
spage1307
epage1313
pages1307-1313
issn0021-972X
formatjournal
genrearticle
ristypeJOUR
abstractCONTEXT:: Studies suggested a potential value of preablative stimulated thyroglobulin (ps-Tg) on predicting the recurrent and persistent diseases of differentiated thyroid cancer, whereas its correlations with therapeutic response remain uncertain. OBJECTIVE:: To establish the correlation between ps-Tg and therapeutic response proposed in 2015 American Thyroid Association guidelines, and calculate a cutoff ps-Tg threshold for predicting a poor response. DESIGN/SETTING:: Patients who underwent total thyroidectomy and radioactive iodine therapy in a university hospital participated in this retrospective study. PATIENTS:: Totally, 452 patients with differentiated thyroid cancer were followed for a median of 38 months and were divided into three groups in terms of ps-Tg level: group 1, less than 1 ng/ml (n = 82); group 2, 1–10 ng/ml (n = 173); and group 3, at least 10 ng/ml (n = 197). MAIN OUTCOME MEASURE:: Clinical outcomes were assessed based on response to therapy restaging system, dividing responses into excellent, indeterminate, biomedical incomplete, and structural incomplete (SIR). RESULTS:: Therapeutic responses could be obviously distinguished by different ps-Tg strata. SIR was identified in none of group 1, 1.73% of group 2, and 42.74% of group 3, respectively (χ = 123.037, P < .001). A cutoff value of ps-Tg at 26.75 ng/ml was obtained by receiver operating characteristic curve for differentiating SIR from either excellent, indeterminate, or biomedical incomplete responses. The area under curve was 0.947 and negative predictive value was 96.99%. Ps-Tg was an independent predictive variable of SIR (odds ratio, 42.312; P < .001). CONCLUSIONS:: Ps-Tg has a great performance in predicting therapeutic response and providing incremental value for decision making of radioactive iodine therapy, especially for patients with high ps-Tg level.
pubCopyright © 2016 by The Endocrine Society
doi10.1210/jc.2015-4016
eissn19457197
date2016-03